Your browser doesn't support javascript.
loading
Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: A multicentre real-world study.
Pezzolo, Elena; Schena, Donatella; Gambardella, Alessio; Rossi, Mariateresa; Barei, Francesca; Calzavara Pinton, Piergiacomo; Girolomoni, Giampiero; Naldi, Luigi; Ferrucci, Silvia Mariel.
Afiliação
  • Pezzolo E; Dermatology Unit, Ospedale San Bortolo, Vicenza, Italy.
  • Schena D; A Study Centre of the Italian Group for the Epidemiologic Research in Dermatology (GISED), Bergamo, Italy.
  • Gambardella A; Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
  • Rossi M; Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
  • Barei F; Section of Dermatology, Department of Medicine, University of Brescia, Brescia, Italy.
  • Calzavara Pinton P; Dermatology Unit, Fondazione Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Girolomoni G; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
  • Naldi L; Section of Dermatology, Department of Medicine, University of Brescia, Brescia, Italy.
  • Ferrucci SM; Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
J Eur Acad Dermatol Venereol ; 38(1): e11-e13, 2024 Jan.
Article em En | MEDLINE | ID: mdl-37483150
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dermatite Atópica Limite: Adult / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dermatite Atópica Limite: Adult / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article